Cell and gene therapies are achieving incredible outcomes for some patients, but they also come with high price tags. How are payers and insurers reacting? We spoke with Fran Gregory, Vice President of Emerging Therapies at Cardinal Health, to get her insight on the topic. She discusses the advances being seen in the space and what payers look for when it comes to reviewing these medicines.
Grab a coffee (or your beverage of choice), get comfy and watch the video discussion below.
About Fran Gregory:
Fran Gregory, PharmD, MBA, is Vice President of Emerging Therapies at Cardinal Health, where she is responsible for Cell & Gene Therapies and Biosimilars. Fran’s background includes extensive clinical, HEOR, trade and commercial experience in the payer/PBM, specialty pharmacy, and biotech manufacturer spaces. Her career reflects a consistent focus on complex, innovative, high-value pharmaceuticals, and a passion for breaking down barriers to access and care.
Throughout her career she has paved the way in innovation by starting two of the first and largest specialty pharmacies in the US, launching two of the first cell and gene therapies in the world, and bringing several first-to-market biosimilars to patients. As a pharmacist, she has an acute focus on patient outcomes, and is an expert in value-based care models, reimbursement and payment strategies, as well as navigating successful teams in healthcare to deliver solutions to bring advanced therapies and treatments to patients.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
